Auto-generated from public data. Not the firm's stated position.
Valide appears to focus on early-stage investments across biotech and enterprise software, with a particular interest in innovative applications including healthcare operations, immersive training technologies, and sustainable processing. Recent portfolio activity suggests the firm targets pre-seed and seed stage companies with check sizes ranging from €0.1M to €1.5M, positioning itself as an early-stage backer of technology-driven solutions.
Generated 15 Oct 2026 from disclosed sectors, stages, and portfolio companies. Firms can update this by emailing [email protected].
Focus and check size from the firm's website. Website reachable as of Oct 2026.
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.